Urica Therapeutics, Inc. (“Urica”) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia. Urica acquired the rights to develop and commercialize Dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union, Canada, Middle East and North Africa (MENA) and Turkey from Fuji Yakuhin. Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase 1 clinical trial in the United States. Urica was founded by Fortress Biotech, Inc. (Nasdaq: FBIO).
Company Details
- Employees
- 1
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://uricatherapeutics.com/
- Keywords
- APTUS BioScience.
Urica Therapeutics, Inc. Questions
Urica Therapeutics, Inc.'s website is https://uricatherapeutics.com/
Urica Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/urica-therapeutics
Urica Therapeutics, Inc. has
1 employees.
View email and phone details for 1
employees at Urica Therapeutics, Inc..
Urica Therapeutics, Inc.'s industry is
Biotechnology Research
Urica Therapeutics, Inc.'s top competitors are
Genassist Ltd,
Hcw Biologics,
Bc Marketing Consulting,
Avenue Therapeutics,
Transgenex Nanobiotech, Inc.,
Uniquity Bio,
Harbour Biomed,
Aptus Bioscience,
Fortress Biotech,
Corregene Biotechnology.
Urica Therapeutics, Inc.'s categories are Biotechnology Research
